Function hub
Sexual-health peptides (UK research overview)
The sexual-health peptide segment is small. PT-141 (Bremelanotide) is the best-known compound, FDA-approved in the US for premenopausal Hypoactive Sexual Desire Disorder (HSDD) but not UK-licensed. Kisspeptin is a research-tier compound with reproductive-axis interest.
The peptide-research segment for sexual health is small but distinctive because of one FDA-approved compound: PT-141 (also known as Bremelanotide, brand name Vyleesi in the US).
PT-141 is a melanocortin-receptor agonist (acting on MC1R and MC4R). FDA-approved in 2019 for premenopausal HSDD. It is not licensed by the MHRA in the UK. UK availability is research-tier through research peptide retailers. The mechanism is central-nervous-system arousal modulation, not peripheral vascular like sildenafil.
Kisspeptin is a 54-amino-acid peptide that is the primary regulator of GnRH release from the hypothalamus, sitting upstream of the reproductive endocrine axis. It is a research compound with substantial clinical-trial activity in fertility, HSDD, and reproductive endocrinology. UK research stocking is patchy.
This category is intentionally light. The compound encyclopedia (Block 4 of the build plan) will add PT-141 and Kisspeptin entries. Until then, this hub maps the UK retailer surface with CoA tier badges where stocking exists.
Compounds in this category
PT-141 (Bremelanotide)
Encyclopedia buildingMelanocortin-receptor agonist. FDA-approved in US for premenopausal HSDD as Vyleesi. UK-licensed status is research-tier only. Encyclopedia entry building.
Kisspeptin
Encyclopedia buildingReproductive-axis regulator. Substantial clinical-trial activity in fertility and reproductive endocrinology. Encyclopedia entry building.
UK retailers stocking this category
See CoA Trust Index →Ranked by CoA Trust tier (strong, partial, weak). Editorial commentary based on publicly available information. We earn a referral fee when readers click through and convert.
Researchers wanting GLP-1-adjacent compounds (Tirzepatide, Retatrutide, Mazdutide) inside a broader peptide catalogue, plus an adjacent biomarker blood-test service.
Research peptide retailer · BPC-157 £17.99, Tirzepatide from £42.99
Anti-counterfeit-framed UK research peptide retailer leaning hard on Fat Loss as primary nav category (Tirzepatide, Retatrutide, Mazdutide) alongside the broader catalogue. Above 99 percent HPLC and mass-spec verified purity claim. CoA gated by email request. Long-form pillar guides with named author byline and PubMed citations.
Buyers wanting the broadest catalogue of delivery formats (vials + pens + nasals + capsules + topicals) in the UK segment.
Research peptide retailer (US parent, UK subdomain) · BPC-157 £11.46 to £189.22 (volume tiers per SKU)
UK-localised subdomain of US-headquartered Direct Peptides (trademark held by Aspire Labs, Texas). Broadest format coverage in the UK segment: lyophilised vials, pre-mixed pens, nasal-spray stacks, capsules, topical cosmetic peptides. 8 years trading (since ~2017). 20 percent first-order discount on dedicated /first-order/ page.
Frequently asked questions
Is PT-141 legal in the UK?
PT-141 is not UK-licensed. It is FDA-approved in the US under the brand name Vyleesi for premenopausal HSDD. UK research peptide retailers stock it under research-use-only framing. UK clinical practice does not currently prescribe it.
Is PT-141 the same as Viagra?
No. Mechanism is completely different. PT-141 acts on central-nervous-system melanocortin receptors to influence arousal at the CNS level. Sildenafil (Viagra) acts on peripheral vascular smooth muscle via PDE5 inhibition. They are not interchangeable and not substitutes.
What is Kisspeptin used for?
Kisspeptin is a research compound under active clinical investigation in fertility, HSDD, and reproductive endocrinology. It is not a UK-licensed medicine. UK clinical use is limited to clinical trial settings.
Related on PeptideClear
Editorial position
PeptideClear is a comparison and information service. We do not sell, dispense, prescribe, or recommend a specific product or medication for a specific person. Every page is editorial commentary. Every CTA leads off-site to a verified UK partner. Read our full methodology.